# KPV peptide dosage in the research literature | routes and models

> KPV peptide dosage in research: ~10 nM in vitro, ~100 uM in mouse drinking water, and 1-10 mg/mL topical drops. No validated human dose exists. A cited research-context summary.

The concentrations, routes, and study durations used in cell and animal work — described as research conditions, never as a human regimen.

## Read this first

When people ask about KPV peptide dosage, they usually want a number to take. The honest answer is that there isn't one — no human dose of KPV has been validated, and KPV is sold for laboratory research only. What does exist is a set of concentrations researchers used in dishes and in animals: very small amounts in cell experiments, a steady low concentration in the drinking water of mice, and stronger drops on the surface of the eye in a rabbit study. Those are research conditions for measuring effects, not instructions for people. Everything below describes what was administered to which species, and nothing here is a recommendation.

## KPV peptide dosage in the research literature

KPV peptide dosage in published studies spans a wide range because the route and model differ. In vitro, the active range runs from about 10 nM in intestinal epithelial and immune cells up to low-micromolar concentrations (for example 0.1-10 uM) in other cell systems [1][6]. In vivo, mouse colitis studies used roughly 100 uM KPV delivered in drinking water — a continuous oral exposure rather than a discrete dose [1]. Topical work in rabbit cornea used eye drops at 1, 5, or 10 mg/mL, dosed four times daily for four days [6]. There is no established or validated human research dose [4]. These figures are research parameters; they are reported here to document the literature, not to define a regimen for any person.

## Routes and stability

The routes studied are oral (drinking water; nanoparticle- or hydrogel-encapsulated in colitis models), topical (ocular drops; mucoadhesive and film dressings), and local or intracolonic delivery via biomaterials [1][5][6]. Stability is the recurring constraint: free KPV is susceptible to enzymatic degradation in the gastrointestinal tract and serum, so much of the 2016-2026 work develops carriers — hyaluronic-acid nanoparticles, polysaccharide and double-network hydrogels, and carrier-free self-assembled nanodrugs — to stabilize it and target inflamed tissue, notably via PepT1 [5]. As a small unprotected tripeptide, KPV is expected to be rapidly degraded by peptidases, and no validated human pharmacokinetic half-life has been published [4]. The delivery problem is covered in full on the [KPV oral bioavailability](/oral-bioavailability) page.

## Frequency and duration in the studies

Study schedules were short and model-bound. The rabbit corneal study dosed eye drops four times daily for four days [6]. Mouse colitis work used continuous oral delivery via drinking water rather than scheduled boluses [1]. No human dosing schedule, frequency, or course length is validated, so the questions readers ask about daily use, injection frequency, or how long to continue have research-context answers only — described below as study conditions, not regimens.

---

A regulatory-grade reading of the KPV tripeptide record — each finding marked confirmed, preclinical, or no-human-data and cited to source, and the FDA 503A standing read straight from FDA's own pages; no clinic behind the dossier and nothing here prescribed, dispensed, or sold.